Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Atossa Genetics Inc (NASDAQ:ATOS)

0.5072
Delayed Data
As of Jun 22
 +0.0042 / +0.83%
Today’s Change
0.40
Today|||52-Week Range
4.95
-64.03%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$3.7M

Company Description

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Contact Information

Atossa Genetics, Inc.
2345 Eastlake Avenue
Seattle Washington 98102
P:(206) 588-0256
Investor Relations:

Employees

Shareholders

Other institutional4.28%
Mutual fund holders1.12%
Individual stakeholders0.50%

Top Executives

Steven C. QuayChairman, President & Chief Executive Officer
Kyle GuseCFO, Secretary & Principal Accounting Officer
Janet Rose ReaVice President-Regulatory Affairs & Quality